Cardinal Health's growth faces challenges from tariff risks, regulatory uncertainties, and competitive pressures. Learn more ...

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...